



CAR T-CELL THERAPY. A CANADIAN TIMELINE

The following provides an overview of how long Canadians are waiting to have access to CAR T-cell therapies across Canada and is meant for informational purposes only.

2018

TISAGENLECLEUCEL (KYMRIAH)



pediatric and young adult patients up to and including 25 years of age with B-cell acute lymphoblastic leukemia (pALL) who are R/R after allogeneic stem cell transplant (SCT) or are otherwise ineligible for SCT, or have experienced second or later relapse **AND** adult patients with R/R large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

Health Canada September 2018

CADTH recommendation posted January 2019

INESSS recommendation posted January 2019 pALL

INESSS recommendation posted January 2019 DLBCL

First provincial listing Quebec October 2019, Ontario December 2019, Alberta January 2021

British Columbia November 2022 for out of province access

*Did not go through the pCPA process

2019

AXICABTAGÈNE CILOLEUCEL (YESCARTA)



adult patients with R/R large B cell lymphoma (LBCL) after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), HGBL, and DLBCL arising from follicular lymphoma

Health Canada February 2019

CADTH recommendation posted August 2019

INESSS recommendation posted August 2019

First Provincial listing Québec and Ontario December 2020, Alberta January 2021

British Columbia for out of province access November 2022

2021

IDECABTAGENE VICLEUCEL (ABECMA)



adults with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and who are refractory to their last treatment

Health Canada approved May 2021

CADTH do not recommend November 2021

INESSS Inscription refused September 2021

approved in the EU and US

2021

BREXUCABTAGENE CILOLEUCEL (TECARTUS)



adult patients with R/R mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.

Health Canada approved October 2021

CADTH submission received December 2020

CADTH review initiated January 2021

CADTH final recommendation posted August 2021

INESSS evaluation posted July 2021

pCPA engagement letter issued November 2021

pCPA negotiation process concluded November 2022

First provincial listing Québec November 2022, Ontario December 2022, Alberta January 2023

2022

LISOCABTAGÈNE MARALEUCEL (BREYANZI)



adults with R/R large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma

Health Canada May 2022

CADTH review initiated August 2021

CADTH final recommendation published June 2022

INESSS decision to the minister June 2022

INESSS decision published June 2022

pCPA engagement letter issued January 2023.

pCPA At the current time the negotiation process is not concluded

2022

LISOCABTAGÈNE MARALEUCEL (BREYANZI)



adults with R/R large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma

Health Canada May 2022

CADTH review initiated August 2021

CADTH final recommendation published June 2022

INESSS decision to the minister June 2022

INESSS decision published June 2022

pCPA engagement letter issued January 2023.

pCPA At the current time the negotiation process is not concluded

The following provides an overview of how long Canadians are waiting to have access to CAR T-cell therapies across Canada and is meant for informational purposes only.

2022

TISAGENLECLEUCEL (KYMRIAH)

adult patients with relapsed or refractory grade 1, 2, or 3a follicular lymphoma (FL) after two or more lines of systemic therapy

Health Canada December 2022

CADTH review initiated february 2023

CADTH final recommendation posted September 2023

INESSS no information listed

pCPA under consideration for negotiation



2022

AXICABTAGÈNE CILOLEUCEL (YESCARTA)

adult patients with R/R grade 1, 2 or 3a follicular lymphoma (FL) after two or more lines of systemic therapy

Health Canada December. 2022

CADTH review initiated May 2023

CADTH final review November 2023

INESSS under evaluation

pCPA (not started)



2022

AXICABTAGÈNE CILOLEUCEL (YESCARTA)

adult patients with diffuse large B-cell lymphoma (DLBCL) or high-grade Bcell lymphoma (HGBL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.

Health Canada December 2022

CADTH review initiated June 2022

CADTH final recommendation posted February 2023

CADTH Review report posted June 2023

INESSS decision to the minister June 2023

INESSS decision published June 2023

pCPA letter of engagement issued September 2023



2023

CILTACABTAGENE AUTOLEUCEL (CARVKTYI)

adult patients with multiple myeloma, who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and who are refractory to their last treatment

health canada approval received february 2. 2023

CADTH review initiated October 11. 2022

CADTH final recommendation posted May 17. 2023

CADTH review report posted August 02. 2023

INESSS under evaluation

pCPA under consideration for negotiation



2023

BREXUCABATAGENE CILOLEUCEL (TECARTUS)

adult patients with R/R B-cell precursor acute lymphoblastic leukemia (ALL)

Health Canada March 2023

CADTH submission received september 2022

CADTH review initiated October 2022

CADTH final recommendation posted April 2023

INESSS recommendation posted August 2023

pCPA engagement letter issued May 2023

pCPA negotiation process concluded October 2023

